Turning Vaccine Priority Upside Down: Applying H1N1 Lessons To COVID-19
A successful COVID-19 vaccine candidate will create a critical challenge: who receives the first doses of what is bound to be a constrained supply? Vaccine developers see useful lessons from the 2009 H1N1 outbreak – but a very different priority order.
You may also be interested in...
There has been a dramatic drop-off in routine immunization rates in the US and around the world amid the COVID-19 outbreak. The catch-up effort may complicate the pandemic response efforts.
Ease of manufacturing scale up may determine which candidates advance furthest in the US government's partnership with industry to speed COVID-19 vaccines to patients. Senior government officials also discussed approval standards, how a vaccine would be distributed, and how much the government and Americans could pay in a 16 June press call.
Move to lower doses could ease manufacturing scale-up burden a bit; first eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.